Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bluebird Bio ( (BLUE) ) just unveiled an update.
On February 13, 2025, Bluebird Bio and its partners, Aventis Inc. and Meta Platforms, agreed to terminate Bluebird Bio’s sublease and Meta’s sub-sublease of office space in Cambridge, Massachusetts. Following this termination, Meta will sublease the space directly from Aventis, while Bluebird Bio, which does not occupy the space, has no further involvement.
More about Bluebird Bio
Bluebird Bio, Inc. is a biotechnology company that specializes in the development of gene therapies for severe genetic disorders and cancer. The company’s focus is on transforming the lives of patients by pioneering innovative treatments.
YTD Price Performance: -16.57%
Average Trading Volume: 393,821
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $69.22M
Learn more about BLUE stock on TipRanks’ Stock Analysis page.